Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

2 days ago 3

Maham Fatima

Sun, May 17, 2026 astatine 11:49 PM CDT 2 min read

Palisade Bio Inc. (NASDAQ:PALI) is 1 of the best NASDAQ stocks nether $5 to bargain close now. On May 12, Palisade reported Q1 2026 earnings, signaling a nett summation successful operating expenses to money its objective pipeline. R&D expenses roseate to $6.4 cardinal for the quarter, compared to $1.0 cardinal successful Q1 2025, driven by higher employee-related costs, chemistry, manufacturing, and controls/CMC expenses, and objective proceedings costs for PALI-2108. G&A expenses besides accrued to $4.4 million, up from $1.4 cardinal successful the anterior year’s period, owed to higher nonrecreational fees and non-cash share-based compensation.

The institution highlighted the continued objective advancement of its pb candidate, PALI-2108, a once-daily, orally administered PDE4 inhibitor prodrug designed for targeted transportation to the terminal ileum and colon to dainty inflammatory bowel disease/IBD. Following affirmative Phase 1a/b information successful ulcerative colitis/UC, Palisade Bio reported encouraging information from its Phase 1b fibrostenotic Crohn’s illness cohort. The results showed sustained progressive metabolite vulnerability supra indispensable thresholds, favorable organisation to colon tissue, and modulation of cardinal inflammatory and fibrotic pathways.

Palisade Bio (PALI) Reports Q1 2026 Results arsenic R&D Expenses Rise to $6.4M

Palisade Bio Inc. (NASDAQ:PALI) plans to taxable an IND exertion for a Phase 2 UC proceedings successful Q2, aiming for proceedings initiation successful Q3 and a superior efficacy readout successful H2 2027. Additionally, an IND submission for a Phase 2 Crohn’s illness proceedings is expected successful H2 2026, targeting proceedings initiation successful Q1 2027 and a superior efficacy readout successful aboriginal 2028.

Palisade Bio Inc. (NASDAQ:PALI) is simply a biopharmaceutical company.

While we admit the imaginable of PALI arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article